Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2015-05-25 Investor Presentation
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Managing Director's Report 6 pages 337.4KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by the Managing Director of Cyclopharm Ltd, dated 26 May 2015, covering the financial highlights, operating highlights, profit and loss, balance sheet, and business outlook for the fiscal year 2014 (FY14). It includes specific financial figures such as sales revenue, net profit after tax, cash flow, and debt repayment. The document also discusses product performance, market expansion, clinical trials, and future growth prospects. The presence of slides and detailed financial and operational data indicates this is a presentation aimed at investors or shareholders summarizing the company's performance and strategy. It is not a full annual report (10-K), nor is it a brief earnings release or a regulatory filing. The format and content align with an Investor Presentation (IP).
2015-05-25 English
Results of Meeting 3 pages 242.3KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of Annual General Meeting on 26 May 2015' and contains detailed voting results for multiple resolutions passed at the AGM, including items on remuneration, re-election of a director, share buy-back, share issuance, and amendments to incentive plans. It references compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, which govern disclosure of voting results. The document is concise (3,738 characters) and focuses solely on the official announcement of voting outcomes rather than the meeting materials or full reports. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2015-05-25 English
Notice of Annual General Meeting/Proxy Form 30 pages 584.4KB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting and Explanatory Statement' for Cyclopharm Limited, detailing the agenda, resolutions to be voted on, and explanatory notes for the AGM scheduled on 26 May 2015. It includes information on ordinary business such as financial statements receipt, remuneration report adoption, director re-election, share buy-back, share issuance to managing director, and remuneration increase for non-executive directors. It also covers special business related to amendments to the Long Term Incentive Plan. The document is a notice and explanatory statement for the AGM, not the actual annual report or financial statements. It is a detailed notice and proxy information for shareholders to vote at the AGM. Therefore, it fits the category of AGM Information (AGM-R).
2015-04-23 English
Annual Report to shareholders 108 pages 1.2MB
Annual Report Classification · 100% confidence The document is titled 'Cyclopharm Limited Annual Report 2014' and contains detailed financial highlights, chairman's letter, managing director's review, directors' report, auditor's independence declaration, corporate governance, comprehensive income statement, financial position, cash flows, changes in equity, notes, directors' declaration, independent audit report, and additional information. It covers the full fiscal year ending 31 December 2014 and includes extensive financial data and analysis. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content matches the definition of an Annual Report (10-K) as it covers company activity and full financial performance for the year. Therefore, the correct classification is Annual Report (10-K). FY 2014
2015-03-30 English
Investor Presentation 15 pages 797.6KB
Investor Presentation Classification · 95% confidence The document is titled 'Cyclopharm Limited Investor Presentation March 2015' and contains detailed information about the company's business lines, financial highlights for FY14, operating highlights, sales revenue, market expansion, new product indications, joint ventures, and outlook. It includes charts, financial data, and strategic growth plans. The content is structured as a presentation aimed at investors, focusing on financials, strategy, and market position rather than a formal regulatory filing or report. There is no indication that this is an official annual report, audit report, earnings release, or other regulatory filing. The length (12,100 characters) and detailed content support that this is a full investor presentation document rather than a brief announcement or certification. Therefore, the document best fits the category of Investor Presentation (IP).
2015-03-11 English
Preliminary Final Report 66 pages 767.5KB
Earnings Release Classification · 95% confidence The document is titled 'Cyclopharm Limited Appendix 4E' and references the financial year ended 31 December 2014. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which typically announce the company's full year financial results to the market. The document includes detailed financial performance data, commentary from the Managing Director, segment reviews, and other financial metrics. It is not the full annual report (10-K) but rather a preliminary announcement of full year results. The document length is substantial (15,000 characters), and it contains substantive financial data and analysis, not just a brief announcement or a certification. Therefore, it fits the category of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights. The document is not a full Annual Report (10-K) because it lacks comprehensive disclosures and is labeled as Appendix 4E, which is a preliminary final report announcement. Hence, the best classification is Earnings Release (ER). FY 2014
2015-02-18 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.